ALB and non-small cell lung carcinoma: In Fig. 3, the model-predicted time profile of tepotinib plasma concentration is shown for a typical patient with NSCLC (59 years, 72 kg, serum albumin = 40 g/L, eGFR = 97.28 mL/min/1.73 m2, INR = 1.06) receiving the clinical dose of 500 mg/day tepotinib TF3 with food.